GlassScriptPhysician profile
Diana Vitale
NPI 1265969349
$5,147.08
in general payments reported to CMS, 2019-2025
24 companies · $864 in 2025
The $864 reported for 2025 was more than what 78% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $147 · 2022: $761 · 2023: $1,785 · 2024: $1,590 · 2025: $864.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,239.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,239.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $771.77 | 2022-2025 | Caplyta |
| Supernus Pharmaceuticals, INC. | $750.33 | 2022-2025 | Qelbree, Qelbree |
| Abbvie INC. | $703.48 | 2021-2025 | |
| Corium, LLC | $585.53 | 2022-2025 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $424.31 | 2022-2025 | Rexulti, Abilify Mycite |
| Alkermes, INC. | $418.72 | 2022-2025 | Lybalvi, Aristada |
| Neurocrine Biosciences, INC. | $240.07 | 2023-2025 | Ingrezza |
| Lundbeck LLC | $230.91 | 2022-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $196.32 | 2022-2024 | Trintellix |
| Noven Therapeutics, LLC | $132.60 | 2024-2025 | Xelstrym |
| Ironshore Pharmaceuticals INC. | $111.87 | 2022-2024 | Jornay Pm |
| Teva Pharmaceuticals USA, INC. | $85.25 | 2023-2024 | Uzedy, Austedo Xr |
| Neos Therapeutics, LP | $82.41 | 2023-2024 | Adzenys Xr-Odt |
| Janssen Pharmaceuticals, INC | $70.75 | 2022 | |
| Validus Pharmaceuticals LLC | $58.96 | 2022-2023 | Equetro |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $52.25 | 2025 | Auvelity |
| Idorsia Pharmaceuticals US INC | $43.34 | 2023 | Quviviq |
| Avion Pharmaceuticals | $40.45 | 2023 | Methylphenidate Hydrochloride |
| Collegium Pharmaceutical, INC. | $39.56 | 2025 | Jornay Pm |
| Vanda Pharmaceuticals INC. | $28.07 | 2025 | Fanapt |
| Indivior INC. | $24.38 | 2023 | Perseris |
| Sunovion Pharmaceuticals INC. | $22.59 | 2022 | |
| Owp Pharmaceuticals, INC. | $16.82 | 2023 | Lamotrigine, Subvenite |
| Tris Pharma INC | $16.34 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diana Vitale listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.